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Abbreviations: 
Co-IP: co-immunoprecipitation 
ChIP: chromatin immunoprecipitation 
TAP: tandem affinity purification 
PPI: protein-protein interaction 
PNI: protein-nucleic acid interaction 
TIP: two-step co-immunoprecipitation 
bTIP: bridged two-step co-immunoprecipitation 
bTChIP: bridged two-step chromatin immunoprecipitation 
LC/MS: liquid chromatography and mass spectrometry 
LFQ: label free quantification 
FC: fold change 
Ig(s): immunoglobulin(-s) 
ab(s): antibody(-ies) 
mAb(s): monoclonal antibody(-ies) 
pAb(s): polyclonal antibody(-ies) 
qPCR: quantitative polymerase chain reaction  
PMA: phorbol 12-myristate 13-acetate 
PAGE: polyacrylamide gel electrophoresis 
CD95(L): cluster of differentiation 95 (ligand) 
IKK: Inhibitor of kappa B Kinase 
DISC: death inducing signaling complex 
APO-1: apoptosis antigen 1 
FADD: FAS-associated protein with death domain 
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SUMMARY 
Co-immunoprecipitation (co-IP) is one of the most frequently used techniques to study protein-protein (PPIs) 
or protein-nucleic acid interactions (PNIs). However, the presence of co-precipitated contaminants is a well-
recognized issue associated with single-step co-IPs. To overcome this limitation, we developed the two-step 
co-IP (TIP) strategy that enables sequential co-immunoprecipitations of endogenous protein complexes. TIP 
can be performed with a broad range of mono- and polyclonal antibodies targeting a single protein or 
different components of a given complex. TIP results in a highly selective enrichment of protein complexes 
and thus outperforms single-step co-IPs for downstream applications such as mass spectrometry for the 
identification of PPIs and quantitative PCR for the analysis of PNIs. We benchmarked TIP for the 
identification of CD95/FAS-interacting proteins in primary human CD4+ T cells, which recapitulated all 
major known interactors, but also enabled the proteomics discovery of PPM1G and IPO7 as new interaction 
partners. For its feasibility and high performance, we propose TIP as an advanced tool for the isolation of 
highly purified protein-protein and protein-nucleic acid complexes under native expression conditions. 
 
 
INTRODUCTION 
Unraveling the complexity and dynamic behavior of protein-protein (PPIs) and protein-nucleic acid 
interactions (PNIs) that serve as central hubs for coordinated cellular events is one of the major objectives in 
cell biology and especially in proteome research (1). A powerful tool for the identification of protein 
networks is affinity purification coupled to mass spectrometry (AP-MS) applying highly sensitive, selective 
and fast scanning tandem MS systems (2). In order to elucidate correct complex stoichiometry, quantitative 
AP-MS is also used for relative and absolute protein quantification (3, 4). 
Co-immunoprecipitation (co-IP) is a predominant method for affinity purification of PPIs and PNIs. This 
strategy employs antibodies directed against the protein of interest to enrich the protein and its interactors 
from a cellular lysate. Co-IP is typically coupled to a number of detection methods, such as western blotting 
or mass spectrometry for identification of PPIs and nucleic acid amplification or sequencing for 
identification of PNIs (4). However, the gentle lysis and washing conditions essential for maintaining the 
integrity of the complexes result in co-purification of non-specific binders that affect all downstream 
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applications. These false-positive interactors interfere with the identification of low abundant complex 
members, even though sophisticated mass spectrometry and data analysis methods help to discriminate 
between specific and non-specific binders (5, 6).  
Approaches that increase the purity of the samples largely overcome this issue, and a widespread strategy has 
exploited the fusion of two separate tags for affinity purification on a single protein. Utilizing each tag 
sequentially, Tandem Affinity Purification (TAP) results in cleaner samples that can be used for 
identification by mass spectrometry, or for other downstream applications (7-15). Yet, the epitope tags need 
to be artificially added to the bait of interest, which in some cases may alter its functions and interactions. 
This also prevents the application of TAP to biological material (e.g. patient samples) that cannot be 
genetically manipulated. 
To achieve high quality affinity isolations of protein-containing complexes without ectopic protein 
expression, we developed the two-step co-immunoprecipitation (TIP) method. TIP consists of two serial co-
IPs using a biotinylated antibody (ab) directed against the endogenous protein. An anti-biotin resin enables 
the gentle elution of the protein complex prior to re-precipitation with protein A/G beads. Alternatively, the 
second co-IP can be performed with abs directed to the same bait or another component of the same 
complex. Here we exemplify the broad applicability of TIP by using several bait proteins and different 
readouts. In particular we focused on the CD95/FAS ‘death inducing signaling complex’ (DISC) and the 
IKK-complex, which have been both extensively studied and have essential functions in key immunological 
processes such as apoptosis signaling and NF-kB activation, respectively (16-19). In contrast to conventional 
single-step co-IP, TIP resulted in highly specific complex purifications as well as identification and 
quantification of all yet known DISC core components by MS. We also demonstrated that TIP could be 
streamlined by applying a biotinylated bridging (secondary) ab (bTIP), thus avoiding the need to modify the 
bait-specific antibodies. Finally we underlined the functionality of TIP in primary human CD4+ T cells and 
purified CD95/FAS- and IKK-complex interacting proteins in this model system. We confirmed all known 
major binders with high confidence and identified protein phosphatase PP2Cgamma (PPM1G) and 
importin 7 (IPO7), which were so far not described to interact with CD95/FAS. Genetic ablation of PPM1G 
significantly sensitized cells to CD95/FAS-induced apoptosis, indicating that it represents a novel 
CD95/FAS-associated negative regulator for the induction of apoptosis by this prototypic cell death receptor. 
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EXPERIMENTAL PROCEDURES 
 
Cell Culture 
HEK293T, HeLa and HCT116 cell lines were purchased from ATCC (CRL-11268, CCL-2 and CCL-247) 
and BJAB cell line from DSMZ (ACC 757). H9 and SKW6.4 cell lines were a gift from P. Krammer. The 
cells were grown in RPMI (Euroclone, Milan, Italy, cat. no. ECM2001L), DMEM (Euroclone cat. no. 
ECB2072L) and McCoy’s (Thermo Fisher Scientific, Bremen, Germany, cat. no. 36600-021) supplemented 
with 10% FBS (Euroclone cat. no. ECS0180L) and antibiotics (Euroclone cat. no. ECB3001D) at 37°C and 
5% CO2. 
 
Reagents for single-step co-IP, TIP and bTIP 
To perform the co-immunoprecipitation reactions we used IP-lysis buffer (30 mM Tris/HCl (pH 7.4), 120 
mM NaCl, 10% Glycerol, 2 mM EDTA, 2 mM KCl and 1% NP40) supplemented with Complete EDTA-free 
protease inhibitor mixture tablet (Roche Diagnostics, Mannheim, Germany). For the elution we prepared 10 
mM biotin stock solution (10 mM D-biotin, 10 mM bicine, 120 mM NaCl and 2 mM KCl) diluted in IP-lysis 
buffer reaching a final D-biotin concentration of 3.3 mM (pH 7.5). Unless otherwise indicated, standard salts 
and buffers were purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, Missouri, USA).  
The resins used were: protein G beads (GE Healthcare Bio-Sciences, Uppsala, Sweden, cat. no. 17-6002-35), 
protein A/G beads (Santa Cruz Biotechnology, Santa Cruz, California, cat. no. sc-2003) and anti-biotin beads 
(Sigma-Aldrich cat. no. A1559). The antibodies used for co-immunoprecipitations were: anti-IKKα (Santa 
Cruz Biotechnology cat. no. sc-7606), anti-CD95/FAS (APO-1-3 (20)) and anti-Caspase-8 (Santa Cruz 
Biotechnology cat. no. sc-6136). These were biotinylated as described below. For the control samples we 
used biotinylated isotype matched antibodies (Southern Biotech, Birmingham, Alabama, cat. no. 0104-08, 
cat. no. 0105-08 and from Santa Cruz Biotechnology cat. no. sc-2755). For bTIP experiments we used anti-
IKKγ (Santa Cruz Biotechnology cat. no. sc-8330) and anti-CD95/FAS (APO-1-3 (20)) antibodies. In these 
experiments rabbit and IgG3 isotype matched antibodies were used (ProSci, Poway, California, cat. no.3703 
and Southern Biotech cat. no. 0105-01). The secondary bridging antibodies were biotin conjugated goat anti-
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rabbit and goat anti-mouse antibodies (Thermo Fisher Scientific cat. no. A27035 and Invitrogen, Carlsbad, 
California, cat. no. A28176).  
For the application of TIP with two different antibodies, the following reagents were used: biotinylated or 
non-biotinylated anti-CD95/FAS (APO-1-3 (20)), anti-FAS (Santa Cruz Biotechnology cat. no. sc-715), anti-
IKKα (Santa Cruz Biotechnology cat. no. sc-7606), anti-IKKγ (Santa Cruz Biotechnology cat. no. sc-8330) 
and the isotype matched antibodies (Southern Biotech cat. no. 0105-08, 0105-01, ProSci cat. no.3703 and 
Abcam, Cambridge, United Kingdom, cat. no. ab18469). Biotinylated bridging antibodies were the same as 
indicated above. The beads specifically recognizing the second antibodies were anti-rabbit beads (Rockland 
Bioscience, Limerick, Pottstown, Pennsylvania, cat. no. 00-8800-25) and anti-mouse beads (Sigma-Aldrich 
cat. no. A6531). For single-step co-IP experiments we used anti-CD95/FAS (Biolegend, San Diego, 
California, clone DX2, cat. no. 305602) and anti-IgG1 isotype control antibodies (Abcam cat. no. ab18443).  
 
Co-Immunoprecipitation Assays 
Mass spectrometry samples were prepared using 1x108 BJAB or 2-3x107 CD4+ T cells, respectively. The 
cells were washed with cold DPBS (Euroclone cat. no. ECB4004L) and lysed in IP-lysis buffer for 20 min 
on a rotator at a density of 2x107 cells/ml (BJAB) and 4x107 cells/ml (CD4+ T cells). The lysates were 
cleared by centrifugation (14800 RPM for 20 min at 4°C) and subjected to three pre-clearing steps. Two pre-
clearing steps were performed using protein G beads pre-coupled with isotype control antibody (3 µg) and 
the last with empty beads (on a rotator for 30 min at 4°C). Identical amounts of lysates were used for single-
step co-IP, TIP and bTIP. While the mock samples received no antibody, the stimulated and non-stimulated 
lysates for single-step co-IP and TIP were incubated with biotinylated antibodies (3 µg)  (bait-specific and 
isotype control). To avoid problems of antibody aggregation, the lysates for the bTIP samples were first 
treated with non-biotinylated primary antibodies (3 µg) on a rotator for 30 min at 4°C. Afterwards the biotin 
conjugated secondary antibodies (6 µg) were added and incubated for additional 30 min on a rotator at 4°C. 
All other steps were performed under identical conditions. Finally, the anti-biotin beads were added. 	  
For the samples only analyzed by western blot, we used 1 µg of primary and 2 µg of biotinylated secondary 
antibodies.  
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 Single-step co-IP and the first step of TIP or bTIP samples were precipitated for 6-14 h at 4°C on a rotator, 
followed by 4-6 washing steps in IP-lysis buffer. The single-step co-IP samples were then stored at -80°C. 
The proteins bound to the anti-biotin beads were eluted with 3.3 mM biotin solution. We performed two 
consecutive elution steps in 500 µl volume for 10 min with rotation at 4°C. After each elution, the samples 
were centrifuged (3500 RPM for 3 min at 4°C) and the supernatant was carefully transferred into a new tube 
containing protein G beads. The final volume was adjusted to 1.5 ml with IP-lysis buffer and the second co-
immunoprecipitation was performed for 6-14 h on a rotator at 4°C. Afterwards, the beads were washed as 
above  and stored at -80°C until analysis. To determine the optimal duration of the elution, the proteins from 
the supernatants after the biotin elution were precipitated using 10% end volume of TCA (Sigma-Aldrich cat. 
no. T0699) and compared to the bead-bound proteins. 
 
Biotinylation of Antibodies 
1-2 µg of antibody in 100 µl PBS were biotinylated with a 50 fold molar excess of 10 mM EZ-Link Sulfo-
NHS-LC-Biotin (Thermo Fisher Scientific cat. no. 21335). The antibody-biotin reaction was incubated for 
2 h on ice and for additional 30 min at room temperature. To remove excess of unbound biotin, the mixture 
was dialyzed against PBS. To evaluate the antibody binding affinity, 2x105 BJAB cells were stained with a 
serial dilution of the abs in FACS buffer (PBS plus 0.5% BSA) for 30 min on ice. Afterwards, the cells were 
washed 2 times with FACS buffer and stained with goat anti-mouse-PE antibody (Thermo Fisher Scientific 
cat. no. P852) for 20 min on ice. The cells were washed and analyzed by flow cytometry (FACS Canto, 
Becton Dickinson). The constant of dissociation (Kd) values were determined with Prism (GraphPad) 
software from the saturation binding curve analysis (21). 
	  
Sample Preparation for MS Analysis 
The protein G beads were incubated in 25 µL reducing sample buffer at 70 °C for 10 min. and a short (2 cm) 
gel electrophoresis run was performed using a 1.0 mm 12 or 15 wells, 4-12 % BisTris Gel (Invitrogen) in 
MES buffer at 200 V, 300 mA, 50 W for 9 min 30 sec. Gels were stained with Coomassie, the stained part of 
the gel lanes were excised in two pieces. Proteins in the individual gel slices were reduced, alkylated and in-
gel digested with trypsin (Promega, Madison, Wisconsin). Prior to MS analysis, extracted peptides of the two 
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gel pieces were combined, desiccated and dissolved in water, containing 2.5% hexafluoro-2-propanol (HFIP) 
(Sigma-Aldrich cat. no. 10522) and 0.1% formic acid (Biosolve, Valkenswaard, Netherlands, cat. no. 
069141A8) prior to MS analysis. 
 
Liquid Chromatography and Mass Spectrometry 
Peptides from trypsin digestions were separated using a nanoAcquity ultra high performance liquid 
chromatography (UPLC) system (Waters). Peptides were trapped with a constant flow of 5 µL/ min on a 180 
µm × 20 mm nanoAcquity UPLC 2G Trap Column filled with Symmetry C18, 5 µm particles. Sample 
separation was performed on a 100 µm × 100 mm nanoAcquity BEH C18, 1.7 µm analytical column 
applying a constant flow of 400 nL/min. Chromatography was carried out using either a 2h stepped linear 
gradient of solvent A (96.9% water, 3% DMSO, 0.1 % formic acid) and solvent B (99.9% acetonitrile and 
0.1% formic acid) in the following sequence: from 0 to 4% B in 1 min, from 4 to 30% B in 80 min, from 30 
to 45% B in 10 min, from 45 to 90% B in 10 min, 10 min at 90% B, from 90 to 0% B in 0.1 min, and 9.9 min 
at 0% B or 3 h gradient from 0 to 4% B in 1 min, from 4 to 30% B in 140 min, from 30 to 45% B in 15 min, 
from 45 to 90% B in 5 min, 10 min at 90% B, from 90 to 0% B in 0.1 min, and 9.9 min at 0% B. The 
nanoUPLC was coupled online to a nano-electrospray source of a linear ion trap quadrupole (LTQ) Orbitrap 
XL mass spectrometer (Thermo Fisher Scientific). A Pico-Tip Emitter tip type 360 µm OD × 20 µm ID; 10 
µm (New Objective) was used for sample ionization and introduction into the MS. The MS was operated in 
the sensitive mode with the following parameters: ESI voltage was set to 2400 V, the capillary temperature 
was 200 °C and the normalized collision energy was 35 V. The orbitrap filling time was set at maximum of 
500 ms. Full scan MS spectra were acquired in a mass-to-charge ratio (m/z) range from 350–2000 in the 
profile mode with a mass resolution of 60,000 at m/z 400. Simultaneously, six most abundant precursor ions 
from the full-scan MS were selected for MS/MS fragmentation in the LTQ. MS/MS data were acquired in 
centroid mode. Only multiply charged (2+, 3+…) precursor ions were selected for MS/MS. The dynamic 
exclusion list was restricted to 500 entries, with a maximum retention period of 30 s and a relative mass 
window of 10 ppm. 
 
Data Processing and Validation/Protein Identification and Quantification 
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Protein quantification was performed with the MaxQuant software 1.5.3.8 (22) wherein peptide identification 
was performed using the Andromeda (23) search engine integrated into the MaxQuant environment against 
the human SwissProt database (uniprot-organism_9606+reviewed_yes 03/2016, 20274 sequences). The 
peptide mass tolerance for database searches was set to 7 ppm and fragment mass tolerance to 0.4 Da. 
Cysteine carbamidomethylation was set as fixed modification. Variable modifications included oxidation of 
methionine, deamidation of asparagine and glutamine and protein N-terminal acetylation. Two missed 
cleavage sites in case of incomplete trypsin hydrolysis was allowed. Furthermore, proteins were considered 
as identified if at least two unique peptides were identified. Identification under the applied search 
parameters refers to false discovery rate (FDR) < 1% and a match probability of p<0.01, where p is the 
probability that the observed match is a random event.  
Data transformation and evaluation was performed with the Perseus software (version 1.5.2.4) (24). 
Contaminants as well as proteins identified by site modification only and proteins derived from decoy 
database containing reversed protein sequences were strictly excluded from further analysis. Protein ratios 
were calculated by label free quantification (LFQ) comparing experiment and control samples. Filtering for 
quantitative values was applied to have at least two valid LFQ values in three replicates of either the 
experiment or the control group. To avoid zero LFQ values for calculating protein expression levels, values 
equal zero were substituted by the lowest LFQ values of each data set regarded. For statistical analyses, 2-
sample t-tests were performed to calculate differences in the protein abundance between these groups (p-
value <0.01). Proteins were only considered as significantly regulated and ranked as potential PPI complex 
partners if their abundance changed more than +4-fold.  
 
Public Access to Mass Spectrometry Data 
The raw data obtained by mass spectrometry were deposited in the PRIDE (PRoteomicsIDEntifications) data 
repository of the EMBL-EBI (25) with the dataset identifier PXD006700. 
To access the raw data please used the Username (Email) and Password described below. 
Email address or Username: reviewer12786@ebi.ac.uk  
Password: GYScqmqx 
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Software Tools 
Protein quantification was performed with the MaxQuant software 1.5.3.8 (22). 
Peptide identification was performed using the Andromeda software (23). 
Data transformation and evaluation was performed with the Perseus software (version 1.5.2.4) (24). 
 
Silver Staining  
Silver staining was performed with the Silver Quest silver staining kit (Invitrogen cat. no. LC6070) 
according to the manufacturers’ recommendation. 
 
Chromatin IP Assays 
HCT116 cells were plated in 10 cm dishes at a density of 5x106 in McCoy’s medium plus 10% FBS at 37°C 
and 5% CO2 overnight. Afterwards, the cells were treated with 40nM SN38 (Sigma-Aldrich cat. no. I1406) 
for 4 h at 37°C. Chromatin was prepared using a standard protocol (Simple ChIP Plus Enzymatic Chromatin 
IP Kit). The isolated chromatin was co-immunoprecipitated using 2 µg of anti-p53 antibody (Santa Cruz 
Biotechnology cat. no. sc-126) or isotype control IgG2a antibody (Southern Biotech cat. no. 0103-01). ChIP 
was performed using reagents and the protocol of the Simple ChIP Plus Enzymatic Chromatin IP Kit (Cell 
Signaling Technology, Danvers, Massachusetts, cat. no. 9004). The bTChIP samples were incubated with 3 
µg of biotinylated Ig-kappa-specific anti-mouse antibody (BD Pharmingen, San Diego, California, cat. no. 
559750) for 2 h and further incubated for other 4 h in the presence of anti-biotin beads (all steps performed 
on a rotator at 4°C). After 3 washes in low salt ChIP buffer, the chromatin was eluted with biotin buffer as 
described above and again immunoprecipitated with Protein G beads on a rotator at 4°C overnight. The 
single-step ChIP and bTChIP samples were processed according to the protocol supplied by Cell Signaling 
Technology and the DNA purification/precipitation step was performed with chloroform/phenol/isoamyl 
alcohol. The samples were analyzed by quantitative real time PCR with an Applied Biosystems Step One 
plus cycler. The signals obtained from each immunoprecipitation were expressed as a percent of the total 
input chromatin (2% x 2(C[T] 2%Input Sample – C[T] IP Sample), C[T] = CT = Threshold cycle of PCR reaction). The 
values shown represent average and SEM of at least 3 independent biological replicates and p-values were 
calculated by student t test.  
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The primers used were: Human CDKN1A (Cell Signaling Technology cat. no. 6449), Puma (forward primer 
GCGAGACTGTGGCCTTGTGT reverse primer CGTTCCAGGGTCCACAAAGT) (26), alpha satellite 
(Cell Signaling Technology cat. no. 4486S) and RLP30 (Cell Signaling Technology cat. no.7014S). 
 
Ethical Statement 
The blood samples used in this research were obtained from healthy blood donors and anonymously 
provided by the Center for Immunohematology and Blood Bank of the Policlinico Umberto I (University “La 
Sapienza”) in Rome. The donors were informed and signed a written agreement allowing the use of the buffy 
coats for research purposes (M(DON)-Q AID Rev.3 del 17/02/2016). The consent form and the medical 
procedures were approved by the local Ethics Committee of the Policlinico Umberto I, Rome. 
 
Primary Human CD4+ T Cell Isolation  
Peripheral blood mononuclear cells (PBMCs) from healthy human donors were isolated by Ficoll-
Histopaque (Sigma-Aldrich cat. no. 1077) density gradient centrifugation at 1500 RPMI for 20 min at room 
temperature. CD4+ T cells were purified from PBMCs using CD4 MACS beads (Miltenyi Biotec, Bergisch 
Gladbach, Germany, cat. no. 130-045-101). To perform TIP for the IKK-complex, 2x107 freshly isolated 
CD4+ T cells were either left untreated or treated with 500 ng/ml Ionomycin (Sigma-Aldrich cat. no. I3909) 
and 50 ng/ml PMA (Sigma-Aldrich cat. no. P8139) for 10 min. Then the cells were lysed in IP-lysis buffer, 
the lysates were cleared and TIP was performed.	  
For the isolation of the CD95/FAS-complex, CD4+ T cells were first activated and expanded. Freshly 
isolated CD4+ T cells were kept at a density of 2x106 cells/ml and incubated with 1 µg/ml PHA (Sigma-
Aldrich cat. no. L9017) for 16h at 37°C. Afterwards the cells were cultivated in RPMI 1640 supplemented 
with 10% FBS and 25 U/ml IL-2 (Roche Diagnostics cat. no. 11147528001) for 6 days. For the CD95 
isolation 3x107 cells were left untreated or were treated with ILZ-CD95L for 20 min at 37°C, lysed and TIP 
was performed. The purity of CD4+ T cells (> 95%) was analyzed with surface staining using anti-CD4 
antibody (Bio-Rad, Serotec, Hercules, California, cat. no. MCA1267) and isotype antibody control (BD 
Biosciences, San Diego, California, cat. no. 345815), data not shown. 
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CD95 Ligand Production  
For the expression of the CD95L, a synthetic FLAG-peptide (DYKDDDDK) and a synthetic ILZ-sequence 
(IEKKIEAIEKKIEAIEKKIEAIEKKIE) were inserted into a eukaryotic expression vector (pcDNA3.1(+); 
Invitrogen) by oligonucleotide-cloning. Supernatant containing highly active recombinant FLAG-tagged 
ILZ-CD95L was produced in HEK293T cells upon transient transfection. 
 
Knockdown of PPM1G 
For the production of shRNAs, HEK293T were co-transfected with the packaging and pseudotyping DNAs 
(psPAX2 and pMD2.G) and pLKO.1 lentiviral shRNA vectors encoding for control and PPM1G targeting 
shRNAs. The packaging constructs were obtained from the ADDGENE consortium, the PPM1G targeting 
sequences used were TRCN0000001214 and TRCN0000001215 (Sigma-Aldrich). For transfection we used a 
standard calcium phosphate transfection method according to the manufacturer’s recommendation (CalPhos, 
Clontech).  
 
Cell Viability Assay 
Control and PPM1G knockdown cells were seeded in equal numbers in a 96 well plate and treated with 
CD95L, Staurosporine (Enzo Life Sciences, Farmingdale, New York, cat. no. ALX-380-014) and ABT-737 
(Abbott Laboratories, Chicago, Illinois, cat. no. S1002). After 24 h the viability was analyzed using Cell 
Titer-Glo Luminescent Cell Viability Assay (Promega cat. no. 47571) and luminescence was analyzed with a 
Perkin Elmer Victor X 3 analyzer. The data shown represent at least 3 independent biological experiments. 
Data are expressed as the mean ± SD using the numbers of replicates reported in the figure legends. 
Statistical analysis was conducted using two-way ANOVA and unpaired Student’s t test *p<0.05; **p<0.01; 
***p<0.001 with Prism (GraphPad) software. To analyze DNA fragmentation, 5x105 BJAB cells were 
treated overnight with ILZ-CD95L, lysed with Nicoletti buffer (0.1% sodium citrate, pH 7.4, 0.1% NP40, 
9.65 mM NaCl, 200 µg/ml RNAse A and 50 µg/ml propidium iodide). The sub-G1/0 nuclei were measured 
by flow cytometry (FACS Canto, Becton Dickinson) and analyzed with FlowJo software 
(https://www.flowjo.com/).  
 
	   13	  
Western Blot and Antibodies 
For the stimulation kinetic, 5x105 BJAB control and PPM1G knockdown cells were treated with ILZ-CD95L 
for the indicated time and then lysed in RIPA buffer (150 mM NaCl, 20 mM Tris/HCl (pH 7.2), 0.05% SDS, 
1.0% Triton X-100, 1% Deoxycholate and 5 mM EDTA) completed with Complete EDTA-free protease 
inhibitor mixture tablet and Phos-STOP phosphatase inhibitor mixture tablet (Roche Diagnostics). The 
lysates were cleared by centrifugation (14800 RPM for 20 min at 4°C).  
For all western blot analyses, the lysates and bead bound proteins were treated with NUPAGE LDS sample 
buffer (Invitrogen cat. no. NP0008) under reducing conditions (50 mM TCEP, Thermo Fisher Scientific cat. 
no. 77720), separated by NuPAGE 4–12% Bis-Tris gradient gel (Invitrogen) using MOPS or MES buffer and 
blotted to a nitrocellulose membranes (GE Healthcare Bio-Sciences). The membranes were blocked for 1 h 
at room temperature with PBST (PBS 0.02% TWEEN20) containing 5% blotting grade non-fat powdered 
milk. 
The antibodies used for western blot were: anti-IKK alpha (Santa Cruz Biotechnology cat. no. sc-7606), anti-
IKK beta (Santa Cruz Biotechnology cat. no. sc-8014), anti-IKK gamma (Santa Cruz Biotechnology cat. no.  
sc-8330), anti-CD95/FAS (Santa Cruz Biotechnology cat. no. sc-715), anti-Caspase 8 (clone C-15 (27)), 
anti-FADD (BD Biosciences cat. no. 610400) and anti-Caspase 3 (Cell Signaling Technology cat. no. 
9665S), streptavidin HRP (GE Healthcare Life Sciences, Pittsburgh, Pennsylvania, cat. no. RPN1231VS), 
anti-β-tubulin (Sigma-Aldrich cat. no. T4026), anti-β-actin (Sigma-Aldrich cat. no. A5441), anti-IPO7C 
(Sigma-Aldrich cat. no. SAB4200152) and anti-IPO7N (Sigma-Aldrich cat. no. SAB4200153) antibodies. 
The anti-PPM1G antibody was a generous gift from Dr. Oliver Gruss (28). All primary antibodies were used 
1:1000 diluted in PBS containing 3% BSA. Western blot quantification was performed using ImageJ 
(https://imagej.nih.gov/ij/) and Image Lab 6.0 software (http://www.bio-rad.com/it-it/product/image-lab-
software). 
 
Experimental Design and Statistical Rationale 
The experiments in this work were designed in order to answer two questions. First we wanted to test 
whether the protein complex isolations performed with TIP or bTIP are more suited to identify PPIs when 
compared to  single-step co-IP. To this end we chose the IKK-complex and the CD95/FAS-DISC, two multi-
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protein complexes for which the composition was largely evaluated before. Thus we had a strong basis to 
determine the identification rates for specific binders. Single-step co-IP, TIP and/or bTIP experiments were 
performed using bait-specific and isotype control antibodies. Three biological replicates were performed for 
each experiment and the isolated proteins were analyzed after applying a two-hour LC gradient. MS-results 
were quantified and potential specific binders were defined as proteins that showed a statistically significant 
(p-value <0.01, student t test) enrichment (>4 fold enrichment) in the samples containing the specific bait 
antibodies. The second rationale was to test whether TIP can be used in discovery experiments using the 
CD95/FAS-DISC and the IKK-complex of stimulated and untreated primary human CD4+ T cells. In this 
case the proteins identified and quantified using specific and isotype-matched antibodies were compared to 
test the feasibility of TIP in a primary cell model: a single experiment was performed and the results were 
compared with the results obtained with biological replicates in the cell line.  
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RESULTS 
Principle of TIP 
In contrast to conventional single-step co-IP (Fig. 1 left panel), TIP consists of two sequential co-
immunoprecipitation steps targeting the endogenous protein(s) (Fig. 1, central panel). The first co-IP is 
performed with a biotinylated bait-specific antibody (biotin-ab), which is captured by anti-biotin beads. 
Alternatively, a biotinylated bridging ab can be combined with a native bait-specific ab (Fig. 1, right panel). 
Unlike avidin and streptavidin resins, the biotin-ab/anti-biotin-ab bond can be efficiently dissociated with 
free biotin, thereby releasing highly enriched complexes consisting of bait protein (bound to potential 
interaction partners) still attached to the biotinylated ab. To complete TIP, another affinity purification step is 
carried out with a standard protein A/G-resin that binds to the Fc-part of the abs (Fig.1). TIP is applicable 
with a number of downstream applications, including the detection of PPIs by western blot analysis or mass 
spectrometry and the detection of PNIs by qPCR.  
 
TIP is Highly Selective and Facilitates the Identification of Complex-Associated Proteins Using 
Monoclonal and Polyclonal Antibodies 
To optimize and benchmark the TIP protocol, we used the well-known CD95/FAS ‘death inducing signaling 
complex’ (DISC). First we biotinylated the anti-CD95/FAS ab, and to rule out a reduced activity due to this 
modification, we compared its affinity with the non-biotinylated ab by flow cytometry. Since the surface 
binding of both was similar, we concluded that the biotinylation had no impact on antibody function (Fig. 
S1a). We chose buffer conditions recently published (29) and tested the optimal precipitation timing for the 
first and second co-immunoprecipitation step. The association of known DISC-components such as 
CD95/FAS, caspase-8 (Casp.8) and FADD (18) was maximal when performing the anti-biotin IP overnight 
(14 h) (Fig. S1b). This is also the time frame frequently published for this complex (29, 30). Under these 
conditions, the anti-biotin resin precipitated the complex at levels comparable to protein A/G beads (Fig. 
S1c). The silver gel analysis suggested that substituting the affinity resin did not result in decreased protein 
background (Fig. S1d). Importantly, the anti-biotin resin enabled an almost quantitative elution of the 
complexes already five minutes after the addition of free biotin (Fig. S1e). We also determined the optimal 
time frame for the second co-immunoprecipitation step and found that caspase-8 (Casp.8) and FADD were 
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efficiently re-precipitated after six hours (Fig. S1f). Therefore the final TIP protocol for this complex 
consists of a first purification overnight and a second precipitation for six hours. To ensure a quantitative 
release of the complexes two applications of the eluent for 10 minutes were applied before the second 
precipitation step. We used these conditions also for the isolation of the IKK-complex and obtained 
comparable results (Fig. S1g-i). 
Next, we performed TIP and single-step co-IP head-to head for the CD95/FAS-DISC using the optimized 
conditions described above. Both methods resulted in equal levels of specifically bound proteins such as 
CD95/FAS, caspase-8 (Casp.8) and FADD, as shown by western blot analysis (Fig. 2a). However, the 
protein pattern obtained by silver staining of a 1D SDS PAGE suggested that the sample complexity was 
significantly reduced in the TIP samples (Fig. 2b). We next tested whether the marked increase in sample 
purity also influenced the identification and quantification of known DISC components by MS. The 
statistical analysis of the label free quantification (LFQ)-values indicated that the strong increase in 
specificity achieved by TIP supported the identification of specific complex binders (Supplementary table 1). 
We set the significance threshold for potential complex binders to a p-value of <0.01 and an enrichment-
factor of >4-fold in the anti-CD95/FAS containing samples when compared to the isotype control. Using 
these conservative settings, the single-step co-IP resulted in the significant enrichment of six proteins. Three 
of these (CASP8, CASP10 and FAS) were already described to be CD95/FAS-DISC components. When 
analyzing the data applying a less stringent threshold (p-value of < 0.05), FADD was also identified as 
CD95/FAS binder while CFLAR and FASLG showed no significant enrichment (Fig.2c, Supplementary 
table 2a). In contrast, the statistical analyses of the TIP samples revealed an enrichment of all six known 
DISC core components (FAS, CASP8, CASP10, FADD, CFLAR and FASLG) (18) in the anti-CD95/FAS 
samples with high confidence (Fig. 2d, Supplementary table 2b). Interestingly, we also obtained significant 
enrichment for 16 additional proteins (Supplementary table 2b and 2c for detailed description of the 
identified proteins), including PPM1G and IPO7 that we later confirmed to interact specifically with 
CD95/FAS (Fig. 2d, blue dots; see below for validation). 
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To test whether TIP was applicable using other antibodies and to validate its broad applicability, we also 
isolated IKKα- and caspase-8 containing protein complexes. We used western blot analyses to investigate the 
recovery of known complex components compared to the single-step co-IP. We found that TIP performed 
with a monoclonal anti-IKKα ab resulted in only a minor decrease of the signals for specific IKK-complex 
binding proteins (IKKα and IKKγ) (16, 31) (Fig. S2a). Also here, 1D SDS PAGE analysis suggested a 
considerable decrease of total protein content in the TIP samples (Fig. S2b). Similar results were obtained by 
isolating caspase-8 associated proteins using a biotinylated polyclonal goat ab (Fig. S2c and S2d).  
In summary, the high specificity of TIP facilitates the identification of specific interactors by MS analysis. 
Our results further indicate that TIP can be performed with mono- and polyclonal antibodies. Thus, TIP 
represents a powerful method for the biochemical isolation and characterization of stable protein complexes 
from native cells. 
 
TIP with Bridging Antibodies 
While we demonstrated above the usefulness of TIP for decreasing the background contaminants and 
improving the detection of specific interactors, biotinylated abs are unfortunately not commonly available 
and biotinylation may reduce their functionality in some cases. Therefore we tested, whether it was possible 
to utilize biotinylated (secondary) bridging abs to perform the TIP protocol. We used recombinant 
oligoclonal abs to standardize the experimental conditions and to avoid batch-to-batch differences of 
polyclonal secondary abs. Compared to the single-step co-IP and TIP, bridged TIP (bTIP) resulted in about 
50% decrease of signal intensity for specifically CD95/FAS-associated proteins such as caspase-8 (Casp.8) 
and FADD as shown by quantitative western blot analysis (Fig. 3a). However, as already observed for TIP, 
bTIP led to a remarkable reduction of sample complexity when compared to the  single-step co-IP as shown 
by 1D SDS PAGE (Fig. 3b) and MS1 base peak chromatograms (Fig. S3a-c). This improved the 
identification of CD95/FAS-associated proteins by MS (Fig. 3c, Supplementary table 1 and Supplementary 
table 3a). Comparable with TIP, MS analyses of the anti-CD95/FAS bTIP samples identified and quantified 
all known major DISC components (FAS, CASP8, CASP10, FADD, CFLAR and FASLG). In addition we 
found significant enrichment of eight additional proteins, including PPM1G and IPO7 (p-value >0.01; Fig. 
3c, blue dots and Supplementary table 3b for detailed description of the proteins identified by TIP).  
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To test whether bTIP could also be applied with polyclonal antibodies (pAbs), we isolated the IKK-complex 
described above by using a rabbit pAb recognizing IKKγ/NEMO (IKBKG). Western blots analysis indicated 
only a slight decrease of signal intensity for the specifically associated proteins IKKα (CHUK) and IKKβ 
(IKBKB) in the bTIP samples when compared to the single-step co-IP (Fig. 3d). However, presumably co-
precipitated contaminant proteins were strongly reduced in the bTIP samples (Fig. 3e). We compared bTIP 
with single-step co-IP by MS. Known complex binders such as CHUK, IKBKB, IKBKG and CDC37 (32) 
were significantly enriched in both anti-IKKγ isolations. Moreover, bTIP resulted in the identification of 
three additional proteins, namely HSP90AA, RELA and NFKB2 (Fig. 3f and g, Supplementary tables 4 and 
5). These proteins were already found to interact with the IKK-complex in a comprehensive TAP-approach 
(32). These results indicated that the identification of specific binders by MS was more efficient in the bTIP 
preparations when compared to the samples isolated by single-step co-IP. We can conclude that TIP can also 
be performed with biotinylated bridging antibodies. 
 
Application of TIP to ChIP 
To investigate if the TIP approach was applicable for other antibody-based assays and to get a quantitative 
estimate of the increased specificity, TIP was adapted to ChIP. To induce p53 activation, the cells were 
treated with the topoisomerase-I inhibitor SN38 and chromatin was co-immunoprecipitated with anti-p53 
(DO-I) or isotype control ab. A bridged two-step chromatin immunoprecipitation (bTChIP) was performed 
as described above and compared to conventional single-step ChIP. The isolated DNAs were quantified by 
qPCRs for promoter regions of p53 target genes (CDNK1A and PUMA) or unrelated chromatin areas 
(RPL30 and α-satellite). In these experiments, bTChIP with both abs (anti-p53 and isotype control) resulted 
in more than 94% signal reduction for non-specific α-satellite repeats and RPL30 (Fig. 4a and 4b). The slight 
decrease of signals for promoter regions of known p53 target genes such as CDKN1A and PUMA was vastly 
over-compensated by 95% loss of non-specific signal with the control ab (Fig. 4c and 4d). This led to an 
impressive increase of the p53/isotype signal ratios for CDKN1A and PUMA promoter regions from 17±2 to 
991±121 and from 7±3 to 100±20 (average±SEM), respectively (Fig. 4e). In summary, we can conclude that 
bTChIP represents an improved alternative to conventional ChIP protocols. 
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Sequential Protein Complex Isolation with Two Different Antibodies 
We further tested whether a modified TIP protocol would enable the purification of protein complexes using 
two abs with different specificities either against the same bait or against two different proteins of the 
complex. This would be useful to distinguish protein complexes that share a common member or if antibody 
cross-reactivity is an important issue. In a first application we tested whether the TIP protocol could be 
performed with two abs recognizing different epitopes of CD95/FAS. To avoid artifacts, we validated that 
the resins used for the second precipitations were not binding the abs used for the initial isolation step (Fig. 
S4a and S4b). Then we purified proteins associated with ligand-stimulated CD95/FAS with a mouse ab 
followed by a re-precipitation of the complex with a CD95/FAS-specific rabbit ab conjugated to an anti-
rabbit resin (Fig. 5a left panel). Next, we reversed the sequence and used first a CD95/FAS-specific rabbit ab 
and biotinylated bridging abs followed by the re-precipitation with a mouse ab and anti-mouse resin (Fig. 5b 
left panel). The western blot analyses indicated that it was possible to isolate interacting proteins such as 
caspase-8 (Casp.8) and FADD by performing the sequential co-IPs in both ways (Fig. 5a and 5b right 
panels). Next, we purified the IKK-complex, and instead of utilizing two abs recognizing one bait protein, 
we sequentially precipitated two different proteins of the complex. In particular we first isolated the IKK-
complex with a mouse ab recognizing IKKα using biotinylated bridging abs and then re-precipitated with a 
IKKγ-specific rabbit ab coupled to anti-rabbit beads (Fig. 5c left panel) and vice versa (Fig. 5d left panel). 
Also in these experiments we were able to isolate the core components of the IKK-complex and got similar 
results by changing the order of the bait proteins (Fig. 5c and 5d, right panels). Thus we provide proof of 
concept that this variation of TIP could be adopted to purify protein complexes with two abs of different 
specificities. 
 
TIP Enables Discovery Proteomics in Primary Human CD4+ T Cells 
Currently the vast majority of protein interaction studies are performed in expandable and genetically 
accessible (tumor-) cells that allow to perform multiple biological replicates and ectopic protein expression. 
Unfortunately, these properties are not shared by most of the primary human cells. 
As a proof of principle, we used TIP to isolate the IKK- and CD95/FAS-complexes from naïve and activated 
human CD4+ T cells, respectively. We obtained human CD4+ T cells from whole blood and performed TIP 
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with anti-IKKα one day after the isolation (Fig. S5a). MS analyses were performed with 3-hour LC 
gradients, and we considered only proteins identified with two or more unique peptides. Also in the primary 
cell system we validated known complex proteins such as IKKα and IKKγ by western blot analysis (Fig. 
S5b). By MS analysis and MaxQuant assisted data processing the known core components of the IKK-
complex were specifically enriched in the anti-IKKα samples (Supplementary table 6). The orthogonal 
comparison with the isotype control samples resulted in 14 and 18 proteins that were only present in the 
IKKα-TIP of resting and PMA/ionomycin stimulated cells, respectively (Fig.S5c). Except for HSP90AA1, 
all known IKK-complex core components (IKBKB, IKBKG, CHUK, HSP90AB1 and CDC37) were only 
found in the stimulated or non-stimulated IKKα-TIP samples, confirming the high specificity and sensitivity 
of TIP. Of note, although it was not passing our stringent criteria excluding all proteins quantified in the 
control, the LFQ value of HSP90AA1 was more than 16 fold higher in the IKKα-TIP compared to the 
isotype control (Supplementary table 6). 
We next performed TIP for CD95/FAS-associated proteins in primary CD4+ T cells from healthy human 
donors activated and expanded for six days in vitro (Fig. 6a). We identified the bait protein (CD95/FAS) and 
all previously described DISC core components such as CASP8, CASP10, FASLG, CFLAR and FADD in 
the CD95/FAS-TIP sample obtained from CD95L stimulated cells (Fig. 6b and 6c). Supporting the published 
constitutive interaction of CD95/FAS and the tubulin cytoskeleton (33), alpha and beta tubulin isoforms were 
identified in a stimulation independent manner (Fig. 6c, Supplementary table 7). Interestingly, importin 7 
(IPO7) and protein phosphatase 1G (PPM1G) were also identified to be associated with CD95/FAS in 
primary CD4+ T cells (Fig. 6c and 6d). In summary these data indicate that TIP enabled the identification of 
PPIs in primary human CD4+ T cells. 
 
PPM1G Knockdown Sensitizes Cells to CD95-Induced Apoptosis 
Besides the well-known interaction partners (CASP8, CASP10, FASLG, CFLAR and FADD), IPO7 and 
PPM1G were the only proteins found to be enriched in the anti-CD95/FAS TIPs performed with the tumor 
cell line that were also identified in primary CD4+ T cells. We verified the interaction of IPO7 and PPM1G 
with CD95/FAS under native conditions using two different antibodies (Fig. 7a). This ruled out an unspecific 
cross-reactivity of the anti-APO1 ab used in the preparative approach. Since PPM1G showed higher 
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sequence coverage in the MS analyses of the samples obtained from primary CD4+ T cells (Fig. 6d), we 
decided to investigate its function in the CD95/FAS signal transduction. Upon binding of CD95L/FASL to 
its cognate receptor, the DISC is formed. The DISC is an activation platform for the so-called initiator 
caspases (caspase-8 and -10) that then cleave and activate effector caspases (e.g. caspase-3 and -7). This 
caspase cascade ultimately leads to the induction of apoptotic cell death. The binding of PPM1G to 
CD95/FAS was detected in various cellular systems (Fig. S6a-c). Down-regulation of PPM1G resulted in a 
3-10 fold increase of CD95L sensitivity in several cell lines (Fig.7b and Fig.S6d). Differently, we have not 
observed any sensitization to other apoptosis inducers such as staurosporine or the Bcl2/XL inhibitor ABT-
737 (Fig. 7c-d). The higher sensitivity for CD95L was due to an increase of apoptotic cell death as 
demonstrated by flow cytometry (Fig.7e) and western blot analysis for the activation of caspases triggered by 
CD95/FAS-stimulation. In cells knocked down for PPM1G expression, DNA fragmentation was also 
detected in absence of CD95L, indicating a mild increase of basal apoptosis in these cells that was not 
evident by western blot analysis (Fig. 7f and Fig S6e). However, the active p18 subunit of caspase-8 (Casp.8) 
was observed two to four hours after CD95L treatment in cells lacking PPM1G, while it accumulated 
significantly less in control cells. The same applied for the fully processed active p17 subunit of caspase-3 
(Casp.3) (Fig. 7f and Fig. S6e). Furthermore, we noted a faster accumulation of the cleaved form of both 
caspase-8 isoforms (p43/41) in the CD95/FAS-DISC formed by PPM1G silenced cells. This was paralleled 
by an increase of the fully activated caspase-8 (p18 subunit) in the DISC of cells lacking PPM1G (Fig. 7g, 
S6f and S6g) and interestingly, in H9 cells we have also detected an increased amounts of non-cleaved 
caspase-8 (Fig. S6f and S6g). In conclusion these results suggest a higher activity of the CD95/FAS-DISC in 
absence of PPM1G indicating its inhibitory role in CD95/FAS-induced apoptosis. 
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DISCUSSION 
TIP combines the advantages of conventional single-step co-IP and TAP (34) for the purification of stable 
protein complexes and overcomes several limitations associated with each of these methods. In contrast to 
TAP (35), the TIP and bTIP approaches do not require the transgenic expression of the bait protein and thus 
can be performed in virtually all cell systems, including primary human cells. The opportunity to work under 
native expression conditions also reduces the risk for non-specific interactions resulting from alterations in 
protein homeostasis (36) or unintended activation of pathways such as apoptosis induction triggered by 
forced expression of CD95/FAS or caspase-8 (37-39). 
TIP and bTIP largely reduced non-specific binders using abs covering different monoclonal mouse IgG 
isotypes as well as commercially available pAbs. Interestingly, in TIP applications rabbit pAbs were as 
effective and specific as mAbs.  
When compared to the single-step co-IP, TIP and bTIP resulted in the identification of more known complex 
components in the CD95/FAS-DISC and the IKK-complex. Indeed, TIP and bTIP resulted in the significant 
enrichment of all so far known and validated core components of the CD95/FAS-DISC formed by this cell 
type (18). The same was obtained for the purification of the IKK-complex with bTIP. In a comprehensive 
TAP-approach published before (32), the TAP-tagged IKKγ/NEMO only identified the core components of 
the complex (CHUK, IKBKB, IKBKG, CDC37, HSP90AA1 and HSP90AB1). In our bTIP experiments we 
also identified these proteins as IKKγ/NEMO interactors without the need of bait protein overexpression. 
With a p-value of 0.051, HSP90AB1 was the only known interactor not unambiguously identified by bTIP. 
Even more, we identified with RELA and NFKB2 two other known proteins of the IKK-complex that were 
not found before when IKKγ/NEMO was used as bait-protein for TAP (32). We want to emphasize that the 
quality of the abs used for the experiments is of highest importance to avoid inefficient precipitation or 
abundant non-specific interactions that are due to poor affinities or cross-reactivity of many commercially 
available abs (40, 41). Fortunately, this problem is known and currently there is a strong tendency of 
companies and researchers to shift towards high quality reagents such as recombinant or rabbit monoclonal 
abs. To circumvent problems with cross-reactivity, we demonstrated that TIP could also be used to 
precipitate protein complexes with two different abs. This facilitates a stringent purification of a complex 
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even with two less specific abs and opens the opportunity to use two abs recognizing two independent 
proteins in the same complex. 
We also demonstrated that TIP is not only suited to investigate PPIs, but can also be adapted to chromatin 
immunoprecipitation. Combined with ORGANIC (42) it may be used to perform high quality sequential 
purifications of chromatin bound transcription factors under native conditions, which was until now not 
compatible with the re-ChIP protocol (43). We also expect that the increased specificity obtained by bTChIP 
will facilitate ChIP sequencing approaches.  
TIP resulted in the identification of IPO7 and PPM1G as CD95/FAS-binding proteins in primary human 
CD4+ T cells. PPM1G was initially described to bind and dephosphorylate metabotrobic glutamate receptor 3 
(44), regulate Cajal body localization (28), histone phosphorylation (45), p21 stability (46), alternative 
splicing (47), p53 signaling (48), transcription elongation (49) and protein translation (50, 51). Here we 
found this protein as constitutively interacting with the death receptor CD95/FAS. However, the exact 
molecular mechanism of how PPM1G depletion leads to the specific sensitization for CD95L remains to be 
investigated.  
In conclusion we showed that TIP and bTIP could be powerful tools to elucidate the composition of stable 
protein complexes even in primary cells. Therefore we envision a broad spectrum of applications for TIP and 
especially bTIP in affinity based discovery proteomics.  
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FIGURE LEGENDS 
Figure 1. Schematic Representation of TIP and bTIP  
Overview of the TIP and bTIP procedures: the cell lysate can be prepared from unmodified cells. It is 
incubated with a biotinylated antibody (ab) recognizing the bait protein (TIP) or with a primary ab followed 
by a biotinylated bridging secondary ab (bTIP); the first affinity purification is performed with anti-biotin 
agarose. The complexes are released by addition of free biotin, recaptured with protein A/G sepharose and 
eluted for downstream applications (O/N= over night). 
 
Figure 2. Comparison of Single-Step co-IP and TIP  
(a) Representative western blot for the CD95/FAS-complex isolations: 1x107 BJAB cells were used to 
perform single-step co-IP and TIP from untreated (-) and CD95L stimulated (+) cells (LC: biotinylated 
mouse IgG light chain; arrowheads: specific signals). 
(b) Silver staining of a representative SDS-PAGE for the CD95/FAS isolations described above.  
(c) Scatter plot showing the enrichment analysis for CD95/FAS single-step co-IP versus the isotype control 
samples (three replicates each). The dotted square indicates the cutoff used to define significant enrichment 
that was set to a p-value <0.01 (student t-test) and a fold change (FC) >4-fold. Known interacting proteins 
are colored in red and labeled with their gene name. For the full analysis see Supplementary tables 1 and 2a. 
(d) Scatter plot showing the enrichment analysis for CD95/FAS-TIP versus the isotype control samples 
(three replicates each). The cutoff for significant enrichment was defined as in (c). For the detailed analysis 
see Supplementary tables 1 and 2b. Known interacting proteins are colored in red and labeled with their gene 
name; the blue dots represent PPM1G and IPO7; the identified proteins are numbered and described in 
Supplementary table 2c. 
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Figure 3. Comparison of Single-Step co-IP, TIP and bTIP  
(a) CD95/FAS-DISC isolations from 1x107 BJAB cells was performed with anti-CD95/FAS ab (α-APO1) 
using single-step co-IP, TIP and bTIP. Shown is the western blot analysis for the indicated proteins (HC: 
mouse IgG heavy chain). The densitometric analyses of the western blot signal intensities were normalized 
to the single-step co-IP (co-IP) samples. (Means and standard deviation (n=3): CD95(-):  co-IP 1.0±0; TIP 
0.9±0.2; CD95(+):  co-IP 1.0±0; TIP 0.9±0.1; bTIP: 0.7±0.1 ⏐ Casp.8:  co-IP 1.0±0; TIP 1.0±0.1; bTIP; 
0.5±0.1 ⏐ FADD:  co-IP 1.0±0; TIP 1.4±0.1; bTIP: 0.5±0; arrowheads: specific signals). 
(b) Silver staining of a representative SDS PAGE for the CD95/FAS-complex isolations described in (a). 
(c) Scatter plot showing the enrichment analysis for CD95/FAS-bTIP versus the isotype control samples. The 
dotted square indicates the cutoff used to define significant enrichment that was set to a p-value <0.01 
(student t-test) and a fold change (FC) >4-fold (see Supplementary tables 1 and 3a). The known interacting 
proteins are colored in red and labeled with their gene name. The blue dots represent PPM1G and IPO7; the 
identified proteins are numbered and described in Supplementary table 3b . 
(d) Shown is a representative western blot of IKK-complex isolations from 1x107 BJAB cells. These were 
performed with an anti-IKKγ ab either by single-step co-IP or by bTIP (LC: rabbit Ig light chain; 
arrowheads: specific signals). 
(e) Silver staining of a representative SDS PAGE for the IKK-complex isolations described in (d).  
(f) Scatter plot showing the enrichment analysis for IKKγ single-step co-IP versus the isotype control 
samples. The dotted square indicates the cutoff used to define significant enrichment that was set to a p-value 
<0.01 (student t-test) and a fold change (FC) >4-fold. The known interacting proteins are colored in red and 
labeled with their gene name. For the detailed analysis see Supplementary tables 4 and 5a. 
(g) Scatter plot showing the enrichment analysis for IKKγ-bTIP versus the isotype control samples. The 
analysis was performed as described in (f). For the detailed MS results and statistical analyses see 
Supplementary tables 4 and 5b. 
 
Figure 4. TIP Can be Adapted to Chromatin Immunoprecipitation 
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5x106 HCT116 cells were treated with SN38 for 4h. Then chromatin was prepared and precipitated using an 
isotype control ab (MOPC21) or an anti-p53 ab (DO-I) by either standard single-step ChIP or bTChIP. The 
bead-associated chromatin was determined by qPCR for: (a) α-satellite sequences, (b) RPL30 promoter, (c) 
CDNK1A promoter and (d) PUMA promoter. Average and SEM of 3 independent experiments are shown 
(**p<0.01; ***p<0.001; student t test; ns: not significant). 
(e) Comparison of signal-to noise ratio (anti-p53 to the isotype control) upon single-step ChIP and bTChIP. 
Shown are 3 biological replicates using CDNK1A primers (logarithmic scale).  
 
Figure 5. TIP for a Sequential Protein Complex Purification with Two Different Antibodies 
(a) CD95/FAS-complex was isolated from 5x107 CD95L stimulated (+) BJAB cells using a mouse 
biotinylated anti-CD95/FAS (α-APO1) ab and co-immunoprecipitated with anti-biotin beads. After the 
elution, the supernatant was incubated with a rabbit anti-CD95/FAS ab (sc-715) and anti-rabbit beads. 
Western blot analysis for the indicated proteins was performed (LC: rabbit Ig light chain; arrowheads: 
specific signals; asterisks: non-specific signals).  
(b) CD95/FAS-complex was isolated with the same preparation of the cell lysates as above using a rabbit 
anti-CD95/FAS ab (sc-715) in combination with a goat biotinylated anti-rabbit secondary ab and precipitated 
with anti-biotin beads. After the elution, the supernatant was incubated with a mouse anti-CD95/FAS ab (α-
APO1) and the complex was purified with anti-mouse IgG beads. Western blot analysis for the indicated 
proteins was performed (LC: mouse IgG light chain; arrowheads: specific signals; asterisks: non-specific 
signals).  
(c) IKK-complex was isolated from 5x107 BJAB cells using a mouse anti-IKKα and a biotinylated goat anti-
mouse secondary ab and precipitated with anti-biotin beads. After the elution, the supernatant was incubated 
with a rabbit anti-IKKγ ab and the complex was isolated with anti-rabbit beads. Western blot analysis for the 
indicated proteins was performed (HC: rabbit Ig heavy chain). 
(d) The IKK-complex was isolated with the same preparation of the cell lysates as above using a rabbit anti-
IKKγ ab and a biotinylated goat anti-rabbit secondary ab. After the elution, the IKK-complex was re-isolated 
with a anti-IKKα ab and anti-mouse beads. Western blot analysis for the indicated proteins was performed 
(LC: mouse IgG light chain). 
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Figure 6. TIP for CD95/FAS-Complex Purification from Primary Human CD4+ T Cells 
 (a) Scheme describing the treatment of primary human CD4+ T cells before CD95/FAS-TIP isolation using 
3x107 untreated (-) or CD95L stimulated (+) cells.  
(b) Western blot analysis for the indicated proteins isolated from non-stimulated (-) and CD95L stimulated 
(+) primary human CD4+ T cells by CD95/FAS TIP (LC: biotinylated mouse IgG light chain; arrowheads: 
specific signals).  
(c) Venn diagram of the proteins identified and quantified by MaxQuant analysis comparing the isotype 
control-TIP and anti-CD95/FAS-TIP in resting and CD95L-treated samples. The list shows the proteins 
selectively enriched in the anti-CD95/FAS samples (ordered by LFQ values). The proteins in bold represent 
published complex components (for the MS results see Supplementary table S7).  
(d) Sequence coverage of the peptides identified for PPM1G (left) and IPO7 (right). Bold letters indicate the 
peptides identified by LC-MS/MS.  
 
Figure 7. Validation of IPO7 and PPM1G Interaction with CD95/FAS and PPM1G Function 
(a) Co-purification of PPM1G and IPO7 with CD95/FAS using two different anti-CD95/FAS antibodies 
(DX2 and α-APO1) under native expression conditions (arrowheads: specific signals). 
(b) PPM1G knockdown sensitizes cells to CD95/FAS-induced cell death. BJAB cells were knocked down 
with two independent PPM1G shRNAs and treated for 24 h with a CD95L as indicated. Viability was 
determined by cell titer glo assay. Shown are average and SD of eight independent experiments (**p<0.01; 
***p<0.001; ANOVA).  
(c-d) PPM1G knockdown does not sensitize BJAB cells for Staurosporine (c) or ABT-737 (d). BJAB cells 
were knocked down as in (b) and treated for 24 h with the indicated drugs at different dilutions. Viability 
was determined by cell titer glo assay. Shown are average and SD of four independent biological 
experiments. 
(e) DNA fragmentation of BJAB cells silenced for PPM1G expression was analyzed by flow cytometry 16 h 
after CD95L addition. 
	   31	  
(f) The processing of caspases upon CD95L stimulation of the cells described in (e) was investigated. Shown 
is a representative western blot analysis for the indicated proteins (arrowheads: specific signals). 
(g) Analysis of the CD95/FAS-DISC formed by 2x107 BJAB cells transduced with control or PPM1G 
shRNAs. The cells were stimulated with CD95L for the indicated timeframes and CD95/FAS was 
precipitated using α-APO1 ab and shown is a representative western blot analysis for the indicated proteins. 
The total lysate is shown in the lower part (LC: mouse IgG light chain; arrowheads: specific signals). 
	  
 
 
 
 
 
 
 
